On July 31, the Trump administration told 17 major drugmakers to align U.S. medication prices with the lowest prices sold in other countries, or the most-favored-nation price.  The White House instructed drug manufacturers to provide their lowest drug prices to Medicaid patients, and to not offer other developed nations better prices than those in the U.S. 

The administration sent letters to AbbVie, Amgen, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, EMD Serono, Genentech, Gilead, GSK, Johnson & Johnson, Merck, Novartis, Novo Nordisk, Pfizer, Regeneron and Sanofi. If drugmakers “refuse to step up,” the letters said the U.S. government “will deploy every tool in our arsenal to protect American families from continued abusive drug pricing practices,” according to the

See Full Page